News & Media

Interim Results Highlights 2016


Assura plc (“Assura”), the leading primary care property investor and developer, announces its half year results for the six months ended 30 September 2016:

 Continued growth of portfolio, rents and profit

  • 75.2% increase in underlying profit[1] before tax to £19.8 million (2015: £11.3 million)
  • 10.6% increase in investment property, to £1.2 billion (March 2016: £1.1 billion)
  • 3.1% growth in diluted EPRA NAV per share to 47.2 pence (March 2016: 45.8 pence)
  • 9.9% increase in rent roll to £70.1 million (March 2016: £63.8 million)
  • £41.7 million profit before tax (2015: £35.4 million)


Strong balance sheet and cost of debt reducing

  • £200 million new unsecured revolving credit facility signed at initial margin of 150bps
  • Weighted average cost of debt reduced by 56bps to 4.28% (March 2016: 4.84%)
  • Post period end, £100 million notes US private placement agreed at 2.65% fixed for 10 years


Sector leader in a market that is in critical need of investment

  • Growing consensus that primary care must play a bigger role in health provision
  • Significant historical underinvestment in primary care space, many GP premises not currently fit for purpose
  • NHS England’s “General Practice Forward View”, announced in April 2016, further emphasises need for appropriate primary care infrastructure and premises


Well positioned to help alleviate the pressures on primary care infrastructure

  • Strong pipeline with £131 million of acquisitions and developments
  • Current LTV of 34% provides £235 million of investment capacity before reaching the mid-point of our LTV range of 40%-50%, allowing Assura to move quickly as the right investment opportunities arise
  • Scalable, internally managed operating model, with in-house development capability
  • Group operates in fragmented market: portfolio of 363 medical centres compares to a total UK market of close to 9,000 buildings



  • 9% increase in quarterly dividend from January 2017 to 0.60 pence per share

Jonathan Murphy, Interim CEO, said:

“Assura has grown significantly in the first half of the year, reflecting the benefit of completed developments and acquisitions. The Group is well positioned as a sector leader in a market that is in critical need of investment. There is a growing consensus that primary care must play a bigger role in health provision and the Group is ideally placed with the expertise, scale and financial flexibility to help the NHS develop our nation’s primary care infrastructure.”

 For further information, please contact:

Assura plc:

Jonathan Murphy

Orla Ball


Tel: 01925 420660

Gordon Simpson

Tel: 0207 251 3801


This announcement contains inside information as defined in Article 7 of the EU Market Abuse Regulation No 596/2014 and has been announced in accordance with the Company’s obligations under Article 17 of that Regulation.

Presentation and webcast:

A presentation will be held for analysts and investors on 22 November 2016 at 11am London time, with a webcast available from our website or via the following link:

[1] Stated before revaluation gains, share-based payments and other non-recurring items